|
Status |
Public on Jul 10, 2018 |
Title |
sRNA sequencing of liver from lean rats and ZDF rats treated with vehicle or colesevelam |
Organism |
Rattus norvegicus |
Experiment type |
Non-coding RNA profiling by high throughput sequencing
|
Summary |
Colesevelam is a bile acid sequestrant approved to treat both hyperlipidemia and type 2 diabetes, but the mechanism for its glucose lowering effects is not fully understood. The aim of this study was to investigate the role of hepatic microRNA’s as regulators of metabolic disease and to investigate the link between the cholesterol and glucose lowering effects of colesevelam. To quantify the impact of colesevelam treatment in rodent models of diabetes, metabolic studies were performed in Zucker Diabetic Fatty (ZDF) rats and db/db mice. Colesevelam treatments significantly decreased plasma glucose levels and increased glycolysis in the absence of changes to insulin levels in ZDF rats and db/db mice. High-throughput sequencing and real-time PCR were used to quantify hepatic miRNA and mRNA changes, and the cholesterol-sensitive miR-96/182/183 cluster was found to be significantly increased in livers from ZDF rats treated with colesevelam compared to vehicle controls. In summary, these results support that colesevelam likely improves glycemic control through hepatic miR-96/182/183, a mechanism that directly links cholesterol and glucose metabolism.
|
|
|
Overall design |
Examination of miRNA changes in livers of ZDF rats treated with vehicle or colesevelam
|
|
|
Contributor(s) |
Sedgeman L, Vickers K |
Citation(s) |
30160993 |
|
Submission date |
Jul 09, 2018 |
Last update date |
Oct 22, 2018 |
Contact name |
Leslie Roteta Sedgeman |
Organization name |
Vanderbilt University
|
Street address |
2220 Pierce Avenue
|
City |
Nashville |
State/province |
TN |
ZIP/Postal code |
37232 |
Country |
USA |
|
|
Platforms (1) |
GPL18694 |
Illumina HiSeq 2500 (Rattus norvegicus) |
|
Samples (18)
|
|
Relations |
BioProject |
PRJNA480300 |
SRA |
SRP152880 |